Evergreen Nephrology
Evergreen Nephrology is a value-based kidney care company that partners with nephrologists, offering whole-person care and advanced analytics tools.
Secondary Market Price
How Evergreen Nephrology Measures Up
To help you manage your Evergreen Nephrology equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series A
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Evergreen Nephrology's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Evergreen Nephrology Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Evergreen Nephrology's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Evergreen Nephrology is a value-based kidney care company that provides services for individuals with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company partners with nephrologists and healthcare providers to offer care coordination, patient education, advanced analytics, and behavioral health integration. Its model focuses on whole-person care, addressing the physical, mental, and social well-being of patients to slow disease progression and reduce hospitalizations. Founded in 2021 and headquartered in Nashville, Tennessee, Evergreen Nephrology has since grown to a staff of between 201 and 500 employees.
Looking forward, the company plans to continue expanding its resources for nephrology practices and scaling its value-based care model. Recent developments include a funding round in February 2025 that raised $130 million from investors including Oak HC/FT and Rubicon Founders. Additionally, the company's Senior Vice President of Growth, Parin Patel, was selected as a 2026 Nashville Health Care Council Fellow.
- Rubicon Founders
- Oak HC/FT
- K2 HealthVentures
- Co-Founder, Co-Founder Adam Boehler
- Co-Founder, Co-Founder Abe Sutton
- Co-Founder, Co-Founder Matt Kim
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Evergreen Nephrology worth joining?
Deciding whether to join a startup like Evergreen Nephrology depends on your personal career goals and risk tolerance. Tools like Prospect can help you analyze the potential value of your equity offer and compare it to other opportunities in the startup ecosystem.
What should I do with my Evergreen Nephrology stock?
The best strategy for your Evergreen Nephrology stock depends on your financial situation, tax implications, and the company's performance. Platforms like Prospect create personalized, multi-year plans for exercising options and selling shares to help you maximize your returns.
Can you sell Evergreen Nephrology stock?
As a private company, selling Evergreen Nephrology stock is typically restricted to specific events like tender offers or secondary market sales. Tools like Prospect can help you navigate these opportunities by providing tender offer analysis and tracking secondary market prices to help you decide when and how much to sell.
How can I find the value of my Evergreen Nephrology stock?
Valuing stock in a private company like Evergreen Nephrology is challenging because it isn’t publicly traded. Prospect uses proprietary predictive models, trained on data used by VCs, to forecast your equity's potential value and help you understand what it might be worth.
What is Evergreen Nephrology's equity worth?
The ultimate worth of your Evergreen Nephrology equity is its value after taxes and exercise costs are paid. A platform like Prospect can help you calculate this net value by modeling different tax scenarios and creating an optimal exercise strategy.
What is Evergreen Nephrology's stock ticker symbol?
As a private, pre-IPO company, Evergreen Nephrology does not have a public stock ticker symbol. You can use tools like Prospect to track your equity's value and plan for a future liquidity event, such as an IPO.
Can I buy or sell Evergreen Nephrology stock?
Buying stock in a private company like Evergreen Nephrology is typically limited to accredited investors or employees exercising their options, while selling is often restricted to company-approved tender offers. Prospect provides tools to help employees model the financial impact of exercising options and optimize sales during these limited liquidity windows.
What is the criteria to buy or invest in Evergreen Nephrology stock?
Investing in a private company like Evergreen Nephrology is generally restricted to accredited investors participating in funding rounds or employees who have been granted equity compensation. For employees with stock options or RSUs, Prospect offers tools to understand and manage their holdings effectively.
